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Abstract
Background: Endogenous ligands of cannabinoid
receptors (endocannabinoids), in particular ananda-
mide (arachidonylethanolamide), have been recog-
nized as being of crucial importance in a variety of
physiological functions. Plasma concentrations of
anandamide have been measured in a number of
investigations; however, discrepant data on ‘‘normal’’
anandamide plasma concentrations were reported.
Since this might be caused by pre-analytical vari-
ables, we investigated the impact of different sample
handling conditions on measured plasma ananda-
mide concentrations.
Methods: Blood samples were taken from healthy
volunteers in EDTA- or heparin-containing tubes;
whole blood samples were kept at q48C, room tem-
perature, or 378C, respectively, for up to 120 min
before obtaining plasma by centrifugation. Plasma
anandamide concentrations were measured by an
isotope-dilution liquid chromatography tandem mass
spectrometry (LC-MS/MS) method.
Results: A marked time- and temperature-dependent
increase in plasma anandamide concentrations ex
vivo was observed in both EDTA- and heparin-con-
taining tubes. Mean anandamide concentrations
approximately doubled when EDTA samples were
kept at 48C for 60 min before centrifugation wimme-
diately centrifuged, 1.3 mg/L (SD 0.3 mg/L); 2.8 mg/L
(SD 0.5 mg/L) after storage for 60 min; ns12). After
storage of heparinized whole-blood samples for
120 min at 378C, a mean plasma anandamide concen-
tration of 11.9 mg/L (SD 1.8 mg/L) was found. In cell-
free plasma, no increase in anandamide concen-
trations was found.
Conclusion: Anandamide is released from blood cells
ex vivo at a very high rate; therefore, strictly stan-
dardized pre-analytical protocols have to be applied
for plasma anandamide determination.
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Introduction
In the early 1990s, two G-protein-coupled receptors
binding D-9-tetrahydrocannabinol (THC), the major
psychoactive component of marijuana, were charac-
terized (CB1 and CB2) (1–3). Subsequently, amides
and esters of long-chain polyunsaturated fatty acids
have been identified as endogenous ligands of can-
nabinoid receptors; among these ‘‘endocannabi-
noids’’, arachidonylethanolamide (synonym anand-
amide) seems to be the most important (4–6).
During recent years, it has become evident that
the interaction of endocannabinoids and CB receptors
is part of fundamental regulatory mechanisms in
numerous physiological processes.
CB1 receptors have been found in most areas of the
brain, generally with a presynaptic localization, where
they play important roles in controlling neurotrans-
mitter release (7, 8). There is strong evidence that cen-
tral endocannabinoid effects are involved in cogni-
tion, pain processing, mood, memory, control of food
intake and energy balance, and in problem drug use
(9–11). Recently, rimonabant, a CB1 receptor antago-
nist, has been introduced for the treatment of drug
addiction and obesity-related disorders (12).
CB2 receptors have been found primarily in peri-
pheral locations, especially on immune and endothe-
lial cells (3). CB2 receptor-based peripheral endo-
cannabinoid signaling is involved in regulation of the
immune system (13–15), apoptosis (16, 17) and vaso-
motor activity (18–20). Recently, a link between com-
mon CB2 receptor gene polymorphisms and auto-
immune diseases was suggested (21).
Endocannabinoid-inactivating enzymes, particularly
fatty acid amide hydrolase (FAAH), have been pro-
posed as therapeutic targets for a variety of diseases
(22, 23).
Plasma concentrations of anandamide have been
studied in a number of investigations (24–29); inter-
estingly, wide variations of mean plasma anandamide
concentrations were reported in cohorts of healthy
volunteers we.g., Fernandez-Rodriguez et al. (27),
mean anandamide concentration 0.13 mg/L; De Mar-
chi et al. (24), mean concentration 0.9 mg/Lx (conver-
sion of units for anandamide: wnmol/Lx=0.35™wmg/Lx;
wmg/Lx=2.87™wnmol/Lx). In these studies, reliable and
accurate isotope dilution mass spectrometry methods
were applied, but the authors gave no detailed infor-
mation on preanalytical sample handling. Since
nucleated blood cells are known to be capable of both
the release and metabolization of anandamide (30),
preanalytical variables may account for the discrepant
observations on ‘‘normal’’ plasma anandamide con-
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Figure 1 Chemical structure of deuterated anandamide
used for internal standardization.
centrations. Therefore, we decided to study the
impact of these variables on plasma anandamide con-
centrations systematically.
Materials and methods
Analytical method
For anandamide quantification, we used a novel, semi-auto-
mated, isotope-dilution liquid chromatography tandemmass
spectrometry (LC-MS/MS) method. A Waters Alliance 2795
HPLC module coupled to a Waters Micromass Quattro Ulti-
ma Pt MS/MS system (Waters, Milford, MA, USA) was used.
For calibration, pure solutions of anandamide in methanol/
water were used (1–50 mg/L). As an internal standard, four-
fold deuterium-labeled anandamide was synthesized as
previously described (31) (Figure 1); the purity of this mate-
rial was 97.2%.
For protein precipitation, 200 mL of acetonitrile (containing
50 mg/L labeled anandamide) was added to 100 mL of plas-
ma. After vortex mixing and centrifugation at 16,000=g for
15 min, a clear supernatant was obtained and transferred
into HPLC vials. Aliquots of 30 mL of this preparation were
injected onto an extraction column (Waters Oasis HLB col-
umn; 25 mm, 2.1=20 mm). The column was washed for
1 min with water/methanol (95:5 v/v) at a flow rate of 4 mL/
min. Using column switching with a six-port high-pressure
switching valve, the extraction column was then eluted in
back-flush with methanol/1 mM ammonium acetate (90:10
v/v at 0.8 mL/min) and the extract was transferred onto the
analytical column (LiCrospher 100 RP-18, 125=4 mm,
5 mm; Merck, Darmstadt, Germany) kept at 378C. The extrac-
tion column was subsequently washed with acetonitrile/
methanol (50:50 v/v; 1 min at 4 mL/min). The eluate from the
analytical column was transferred at a split ratio of approx-
imately 1:10 to the LC-MS/MS system. Electrospray atmos-
pheric-pressure ionization in the positive mode was used.
The source parameters were set to obtain the protonated
quasi-molecular ions of anandamide and the labeled internal
standard compound (capillary voltage, 2.3 kV; cone voltage,
50 V; source temperature, 1208C; desolvation temperature,
3508C; nitrogen flow, approx. 550 L/h; collision energy, 10 V).
The following transitions were recorded in multiple-reaction
monitoring: anandamide, 348™62; labeled anandamide,
352™66. The retention time of anandamide was approxi-
mately 5.4 min. The method was linear from 0.8 to 50 mg/L
and was reproducible, with inter-assay coefficients of varia-
tion of 6.8% and 5.3% for mean anandamide concentrations
of 2.1 and 12.8 mg/L, respectively (ns12). No significant dif-
ferences in the peak areas of deuterated anandamide were
observed when pure solutions or plasma samples were
spiked, ruling out relevant ion-suppression effects. The low-
er limit of detection of the method (defined as a signal/noise
ratio G4:1) was 0.5 mg/L. A representative chromatogram is
shown in Figure 2.
Experiments
In a first study, 12 healthy volunteers were included after
written informed consent. Blood was collected by venipunc-
ture into five EDTA-containing tubes (S-Monovette EDTA;
Sarstedt, Numbrecht, Germany). One of the tubes was cen-
trifuged within 5 min after venipuncture and plasma was
immediately frozen (y208C). Two tubes were kept at q48C
and were centrifuged after 60 or 120 min, respectively, to
obtain plasma, which was then frozen immediately. Two fur-
ther tubes were kept at room temperature (22–258C) for 60
or 120 min before centrifugation.
In plasma samples obtained immediately after venipunc-
ture, a mean anandamide concentration of 1.3 mg/L was
found (SD 0.3 mg/L). In plasma of samples kept at q48C for
60 and 120 min, mean concentrations of 2.8 mg/L (SD 0.5
mg/L) and 3.8 mg/L (SD 0.4 mg/L), respectively, were meas-
ured (p-0.05; paired Wilcoxon test). In plasma of samples
kept at room temperature, mean concentrations of 3.8 mg/L
(SD 1.0 mg/L) after 60 min and 5.2 mg/L (SD 0.6 mg/L) after
120 min were found (p-0.05). Thus, a significant time- and
temperature-dependent increase in plasma anandamide
concentrations was observed. This may be explained by the
release of anandamide from circulating immune cells (19,
30).
We suspected that this release might in part be the con-
sequence of non-physiological stimulation of leukocytes due
to calcium chelation by EDTA and a temperature below 378C
in the sample tubes. Therefore, in a second set of experi-
ments, we used heparin-anticoagulated whole blood sam-
ples (S-Monovette Lithium-Heparin; Sarstedt) kept atq48C,
room temperature, or 378C for 30, 60 and 120 min. In sam-
ples from five healthy volunteers, a time- and temperature-
dependent increase in anandamide concentrations was
again observed (Figure 3). The most marked increase in
anandamide concentrations was found in samples stored
at 378C; at this temperature, a mean ‘‘D anandamide’’ of 7.5
mg/L (SD 1.4 mg/L) was observed between 30 and 120 min
after venipuncture. Lactate dehydrogenase (LDH), aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
potassium, and glucose were analyzed in the plasma sam-
ples obtained immediately and after incubation at 378C for
120 min, respectively. While glucose concentrations decreas-
ed by a mean of 19%, no significant changes in the concen-
trations of the other analytes were observed.
In a third set of experiments, whole blood samples from
ten healthy volunteers were precipitated with a 4:1 mixture
of methanol/zinc sulfate 50 g/L immediately after sampling
(200 mL of whole blood and 200 mL of precipitation solution);
after centrifugation, supernatants were analyzed for anan-
damide. In all cases the anandamide signal was below the
predefined lower limit of detection (-0.5 mg/L).
To study the stability of anandamide in cell-free plasma,
aliquots of six plasma samples obtained during the incuba-
tion experiments were kept at room temperature for 24 h
prior to analysis (concentration range 2.0–14.0 mg/L). A
decrease in mean anandamide concentration of 9.5% within
24 h was observed.
The investigation protocols for all experiments were
approved by the institutional Review Board.
Results and discussion
We were able to demonstrate extensive release of
anandamide from whole blood cells ex vivo. This
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Figure 2 Representative chromatogram of anandamide and deuterated anandamide used as the internal standard obtained
from a human whole-blood sample (concentration of anandamide, 4.3 mg/L; Y-axis represents the relative intensity of the
signal with respect to the baseline of the chromatogram).
Figure 3 Anandamide concentrations found in plasma of
heparinized whole-blood samples incubated at various tem-
peratures for different time intervals (mean and SD; ns5).
Conversion of units for anandamide: wnmol/Lx=0.35™wmg/Lx;
wmg/Lx=2.87™wnmol/Lx.
release may result from mobilization of pre-existing
anandamide from cellular structures of blood cells,
from de novo synthesis and exocytosis of ananda-
mide ex vivo by blood cells, or from a combination of
both.
To clarify this issue, we precipitated whole blood
samples by adding methanol immediately after veni-
puncture under the assumption that this procedure
would block all metabolic processes and disintegrate
cell membranes. After centrifugation, we found only
trace concentrations of anandamide in the superna-
tant. It cannot be completely ruled out that ananda-
mide in part undergoes co-precipitation with proteins
in this experiment; however, our observation rather
suggests de novo synthesis of anandamide than
release of pre-existing anandamide to cause ex vivo
increases in plasma anandamide concentrations.
We conclude from our results that the determina-
tion of baseline plasma anandamide concentrations
has to follow strictly standardized pre-analytical pro-
tocols with immediate sample centrifugation. Even
if this protocol is followed, it cannot be completely
ruled out that anandamide is released into plasma
during centrifugation.
Stasis, hypoxia, and the foreign surface of a sample
tube may trigger anandamide synthesis and release
from blood cells; the potential of leukocytes to form
anandamide has been demonstrated previously (19,
30). The in vivo baseline rate of anandamide syn-
thesis in these cells under physiological conditions,
however, remains uncertain. Besides preanalytical
considerations, our data demonstrate that blood cells
actually posses a very high anandamide release
capacity in response to stressful stimuli; this may be
of functional relevance for the peripheral CB2 recep-
tor-based endocannabinoid system (14–21).
Furthermore, our results demonstrate the feasibility
of characterizing the anandamide release capacity of
blood cells using a standardized ex vivo sequential
plasma sampling protocol from incubated heparini-
zed whole blood, providing a ‘‘D anandamide’’, e.g.,
between 30 and 120 min after venipuncture. During
this time interval, we found a linear increase in anan-
damide concentrations in samples from healthy vol-
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unteers (Figure 3). We plan to use this sampling
principle in further studies to investigate blood-cell
anandamide synthesis capacity in health and different
disease states.
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